Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer

Inventors

Fucikova, Jitka • Koci, Lenka • Pokorna, Katerina • Truxova, Iva • Moserova, Irena • Rozkova, Daniela • Spisek, Radek

Assignees

Sotio AS

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10561717-B2

Patent

Publication Date

2020-02-18

Expiration Date


Abstract

Described herein is a reliable method for preparing a potent vaccine useful for immunotherapy comprising the step of cryopreserving a population of cells undergoing immunogenic cell death, and using such cells to activate dendritic cells for use in immunotherapy. In a specific embodiment, the method comprises cryopreserving cancer cells undergoing cell death, which can be used to prepare a pharmaceutical composition for immunotherapy against cancer.

Core Innovation

The invention relates to a method for preparing a pharmaceutical composition for use in immunotherapy by inducing immunogenic cell death in a population of cancer cells, cryopreserving the cancer cells undergoing immunogenic cell death in a cryopreservant, thawing the cryopreserved cancer cells, and pulsing immature dendritic cells with the thawed cancer cells. The approach is framed around preparing cancer-cell-derived material that can be stored in cryopreservant and later used for dendritic cell antigen pulsing in an immunotherapy manufacturing workflow.

The problem addressed is the need for an immunotherapy manufacturing approach that can be standardized and can rely on cryopreserved cancer cells while preserving features relevant to immunogenic cell death. The description emphasizes inducing immunogenic cell death in defined cancer cell lines, maintaining immunogenic cell death-related hallmarks after cryopreservation and thawing, and using the thawed cells to pulse immature dendritic cells for immunotherapy.

The invention also specifies characterization of immunogenic cell death by expression of immunogenic cell death hallmarks, including calreticulin, HSP70, and HSP90. Immunogenic cell death is induced using named inducers and physical modalities, including high hydrostatic pressure, and the resulting dendritic cell pulsing and subsequent immune recognition are described through maintained tumor antigen-related features and comparable tumor-specific T-cell responses.

Claims Coverage

The supplied independent claims cover three inventive features: methods of preparing a pharmaceutical composition for ovarian cancer immunotherapy, methods of preparing a pharmaceutical composition for lung cancer immunotherapy, and a cryopreservant-preserved in vitro population of human cells undergoing immunogenic cell death with specified tumor-antigen tumor cell line combinations. The inventive features are expressed as a multi-step workflow and related characterization and cryopreservant constraints.

Ovarian cancer immunotherapy workflow using cryopreserved ICD cancer cells pulsed into immature dendritic cells

A method for preparing a pharmaceutical composition for use in immunotherapy against ovarian cancer comprising inducing immunogenic cell death in a population of cancer cells from cell lines SK-OV-3 and OV-90, cryopreserving the cancer cells undergoing immunogenic cell death in a cryopreservant, thawing the cryopreserved cancer cells, and pulsing immature dendritic cells with the thawed cancer cells.

Lung cancer immunotherapy workflow using cryopreserved ICD cancer cells pulsed into immature dendritic cells

A method for preparing a pharmaceutical composition for use in immunotherapy against lung cancer comprising inducing immunogenic cell death in cancer cells lines NCI-H520 and NCI-H522, cryopreserving the cancer cells undergoing immunogenic cell death in a cryopreservant, thawing the cryopreserved cells, and pulsing immature dendritic cells with the thawed cancer cells.

Cryopreservant-preserved human tumor-cell population undergoing immunogenic cell death for immunotherapy

A population of in vitro in cryopreservant preserved human cells undergoing immunogenic cell death, wherein the cells are a combination of tumor cell lines selected for their expression of the tumor antigens of a tumor to be treated by immunotherapy.

Across the independent claims, the coverage centers on preparing immunotherapy pharmaceutical compositions by inducing immunogenic cell death in specified cancer cell lines, cryopreserving those immunogenic cell death cells in a cryopreservant, thawing them, and pulsing immature dendritic cells with the thawed cells; additionally, the independent scope includes cryopreservant-preserved in vitro human cell populations undergoing immunogenic cell death comprising tumor cell line combinations selected for tumor-antigen expression for the tumor being treated.

Stated Advantages

Standardization and quality-control advantages of an immunotherapy manufacturing approach using cryopreserved tumor cells undergoing immunogenic cell death.

Preservation of immunogenic cell death features after cryopreservation and thawing, including apoptotic and immunogenic cell death hallmarks relevant to immunogenic cell death.

Comparable or improved tumor-specific IFN-gamma T-cell responses versus non-frozen controls as described in the example data.

Documented Applications

Immunotherapy against ovarian cancer using a method that induces immunogenic cell death in SK-OV-3 and OV-90 cancer cells, cryopreserves and thaws the cells, and pulses immature dendritic cells with the thawed cells.

Immunotherapy against lung cancer using a method that induces immunogenic cell death in NCI-H520 and NCI-H522 cancer cells, cryopreserves and thaws the cells, and pulses immature dendritic cells with the thawed cells.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.